



## Community feedback: CROI 2015



Simon Collins  
HIV i-Base  
[www.i-Base.info](http://www.i-Base.info)



SEATTLE, WASHINGTON  
23 – 26 February 2015

CROI 2015 feedback: [www.i-Base.info](http://www.i-Base.info) UK-CAB April 2015




## Prevention and new drugs

- PrEP, prevention
- Drug interactions
- New ARVs
- UK case of remission

Slides compiled from 2015 BHIVA “Best of CROI” feedback meetings.

- CROI talks are all webcast
- BHIVA feedback is also webcast

CROI 2015 feedback: [www.i-Base.info](http://www.i-Base.info) UK-CAB April 2015






## Pragmatic Open-Label Randomised Trial of Pre-Exposure Prophylaxis: the PROUD study

- To determine whether PrEP worked as well as iPrEx in this setting (44% reduction in HIV)
- Possibility that effectiveness might be less in real world

MRC | Medical Research Council

CROI 2015 feedback: [www.i-Base.info](http://www.i-Base.info) UK-CAB April 2015



## PROUD Pilot

MSM reporting UAI last/next 90 days

```

    graph TD
      A[MSM reporting UAI last/next 90 days] --> B[Truvada NOW N= 267]
      A --> C[Truvada AFTER 12M N=256]
      B --> D[Follow 3 monthly for up to 24 months]
      C --> D
      D --> E[Main endpoints in Pilot: HIV infection in first 12 months]
    
```

CROI 2015 feedback: [www.i-Base.info](http://www.i-Base.info) UK-CAB April 2015

## PROUD: Baseline demographics<sup>1</sup>

Characteristics		Immediate	Deferred
Age, median (IQR)		35 (30 – 43)	35 (29 – 42)
Ethnicity	White	80%	82%
Born UK	No	40%	40%
Education	University	59%	60%
Employment	Full-time	70%	73%
Sexuality	Gay	96%	94%
Current relationship	No	53%	55%
Recreational drug use	Yes	76%	64%

CROI 2015 feedback: [www.i-Base.info](http://www.i-Base.info) UK-CAB April 2015

## PROUD: new HIV infections

CROI 2015 feedback: [www.i-Base.info](http://www.i-Base.info) UK-CAB April 2015

### PROUD: HIV incidence rates

Group	No. of infections	Follow-up (PY)	Incidence (per 100 PY)	90% CI
Overall	22	453	4.9	3.4-6.8
Immediate	3	239	1.3	0.4-3.0
Deferred	19	214	<b>8.9</b>	6.0-12.7

**Efficacy** =86% (90% CI: 58 - 96%)  
**P value** =0.0002


**Rate Difference** =7.6 (90% CI: 4.1 - 11.2)  
**Number Needed to Treat** =13 (90% CI: 9 - 25)

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### PROUD: Drug Resistance

- **3 of 6** individuals who were seroconverting as started truvada developed **M184V/I** mutations (as a mixture with wild type)
- **N=0 K65R**

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015



### PROUD: conclusions

- HIV incidence was much higher than predicted
  - Despite extensive use of PEP in the deferred period
- Concerns about PrEP being less effective in the real world unfounded
- There was no difference in STIs, which were common in both groups
- Clinics were able to adapt routine practice to incorporate PrEP...JUST!


CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### On Demand PrEP with Oral TDF/FTC in MSM Results of the ANRS Ipergay Trial

Molina JM, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I, Tremblay C, Meyer L, Delfraissy JF, and the ANRS Ipergay Study Group

Hospital Saint-Louis and University of Paris 7, Inserm SC10-US019 Villejuif, Hospital Tenon, Paris, Hospital Croix-Rousse, Lyon, UMR912 SEAS Marseille, France, CHUM, Montreal, Canada and ANRS, Paris, France

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015



**ipergay**  
ANRS  
Intervention Préventive  
à l'Épandage des Risques  
Sexuels et pour les Gays

### Ipergay : Event-Driven iPrEP

- ✓ 2 tablets (TDF/FTC or placebo) 2-24 hours before sex
- ✓ 1 tablet (TDF/FTC or placebo) 24 hours later
- ✓ 1 tablet (TDF/FTC or placebo) 48 hours after first intake

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

**ipergay**  
ANRS  
Intervention Préventive  
à l'Épandage des Risques  
Sexuels et pour les Gays

### Baseline Characteristics

Characteristics (Median, IQR) or (n, %)	TDF/FTC n = 199	Placebo n = 201
Age (years)	35 (29-43)	34 (29-42)
White	190 (95)	184 (92)
Completed secondary education	178 (89)	177 (89)
Employed	167 (85)	167 (84)
Single	144 (77)	149 (81)
History of PEP use	56 (28)	73 (37)
Use of psychoactive drugs*	85 (44)	92 (48)
Circumcised	38 (19)	41 (20)
Infection with NG, CT or TP**	43 (22)	59 (29)
Nb sexual acts in prior 4 weeks	10 (6-18)	10 (5-15)
Nb sexual partners in prior 2 months	8 (5-17)	8 (5-16)

\* in last 12 months: ecstasy, crack, cocaine, crystal, speed, GHB/GBL  
 \*\* NG: Neisseria gonorrhoeae, CT: Chlamydia trachomatis, TP: Treponema pallidum

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

**ipergay**  
ANRS  
Intervention Préventive  
à l'Épandage des Risques  
Sexuels et pour les Gays

### STI & Sexual Behavior

No difference between groups in any STI

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

**ipergay**  
ANRS  
Intervention Préventive  
à l'Épandage des Risques  
Sexuels et pour les Gays

### KM Estimates of Time to HIV-1 Infection (mITT Population)

Log-rank test p = 0.002

Mean follow-up of 13 months: 16 subjects infected  
 14 in placebo arm (incidence: 6.6 per 100 PY), 2 in TDF/FTC arm (incidence: 0.94 per 100 PY)  
 86% relative reduction in the incidence of HIV-1 (95% CI: 40-99, p=0.002)  
 NNT for one year to prevent one infection : 18

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

**ipergay**  
ANRS  
Intervention Préventive  
à l'Épandage des Risques  
Sexuels et pour les Gays

### Adherence

- PILL COUNT
  - Median number of pills/month (IQR): 16 pills (10-23) in the placebo arm and 16 pills (12-24) in the TDF/FTC arm (p=0.84) ie 50% of daily
  - 20% took over 25 pills a month, i.e. the equivalent of almost daily
  - 20% less than four, i.e. less than one a week.
- LAST SEX
  - 43% used correct regime

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

**ipergay**  
ANRS  
Intervention Préventive  
à l'Épandage des Risques  
Sexuels et pour les Gays

### Conclusions

- incidence of HIV-1 infection in placebo arm was higher than expected
- "On Demand" oral PrEP with TDF/FTC was very effective with a 86% (95% CI: 40-99) reduction in HIV-incidence
- Adherence was good
- Safety of "on demand" TDF/FTC was overall similar to placebo except for gastrointestinal AEs
- No evidence of risk compensation





CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### Near elimination of HIV transmission in a demonstration project of PrEP and ART

Jared M. Baeten, Renee Heffron, Lara Kidoguchi, Nelly Mugo, Eily Katabira, Elizabeth Bukusi, Stephen Asimwe, Jessica E. Haberer, Deborah Donnell, Connie Celum, for the Partners Demonstration Project Team

*CROI 2015, Seattle*

PARTNERS DEMONSTRATION PROJECT

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015


### New Partners PreP cohort

- Enrolled HIV serodiscordant couples not on ART or PrEP who scored high on 'risk score'
  - Young, sex
- TASP and PrEP offered to couples

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### PrEP as a bridge to ART


- For couples initiating ART at enrollment, PrEP is offered through 6 months, then stopped:



ART →

PrEP → Stop

- For couples in which the infected partner delays or declines ART, PrEP is continued until 6 months after ART initiation:



ART delayed..... ART →


PrEP → Stop

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

N=2 transmissions: both not on TASP or Prep (Expected annual HIV incidence 5.2%)


### HIV incidence

- The observed incidence is a **96% reduction** compared to expected, a result that was highly statistically significant



1<sup>st</sup> study showing low incidence in extra marital infections

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015



**FACTS**  
Follow-on African Consortium  
for Tenofovir Studies

## FACTS 001: a multi-centred phase III randomised, double-blind, placebo-controlled trial of pericoital tenofovir 1% gel for HIV prevention in women


Helen Rees, Sinead Delany-Moretwe, Carl Lombard, Deborah Baron, Ravindre Panchia, Landon Myer, Jill Schwartz, Gustavo Doncel, Glenda Gray on behalf of the FACTS 001 study group

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### FACTS 001: Primary Objective

To evaluate the safety and effectiveness of pericoital tenofovir (TFV) 1% gel applied intravaginally in preventing HIV-1 infection in women.

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015



### FACTS 001: Baseline characteristics

	TFV gel N= 1015 % or median (IQR)	Placebo gel N=1014 % or median (IQR)
Mean Age (years)	23 (20 – 25)	23 (20 – 25)
<25 years	71%	70%
Single	89%	89%
Living with parents/siblings	61%	63%
Secondary education or higher	56%	56%
Anal sex *	1%	1%
Consistent condom use*	35%	32%
Perceived HIV risk > than usual*	18%	17%
Median no. of sex partners*	1 (1- 1)	1 (1- 1)
HSV-2 seroprevalence	43%	40%

\*in the past 28 days

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### FACTS 001: No difference in HIV incidence between TFV gel vs placebo

	TFV gel	Placebo gel
Person-years	1515	1521
Protocol-specified HIV endpoints	61	62
HIV incidence per 100 p-y (95% CI)	4.0 (3.1-5.2)	4.0 (3.1-5.2)

**Incidence Rate Ratio (IRR) 1.0; 95% CI: 0.7-1.4 \***

\*stratified by site

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### FACTS 001: Case-cohort sample of Tenofovir detection in CVL

- 56 HIV cases, 158 controls (n=214)

Percent of <b>samples</b> with any TFV detected*	64%
Percent of <b>women</b> with: TFV <b>never</b> detected at quarterly visits	13%

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### FACTS 001: Tenofovir detection and HIV incidence

TFV exposure	Adjusted Hazard Ratio (95% CI)	Protection (%)	P-value
TFV detected in samples from women who reported sex in 10 days preceding CVL	0.48 (0.23 - 0.97)	52	0.04

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### FACTS 001: Conclusion

- Pericoital vaginal TFV 1% gel was safe, but not effective in preventing HIV acquisition
- Effectiveness limited by adherence

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

**Levonorgestrel Implant + EFV-Based ART: Unintended Pregnancies and PK Data**

- Kimberly K. Scarsi
- *University of Nebraska Medical Center, Omaha, NE, United States*

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

**Implanon- Levonorgestrel implant**

- Failure rate <1%
- Long acting: 4-5yr
- Metabolized by cyp P450 3A4
- Constant drug exposure but slow decline
  - Need 180mcg/day levels to prevent pregnancy

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

- Non randomized open label parallel group pk study in Uganda
  - EFZ group: HIV implant + starting EFZ based regime
  - Controls: HIV + implant only
- 48 weeks
  - Drug levels & PT every 3-,months

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

**Results**




- 20 women in each group
- PK : Comparing EFZ and control group
  - ~50% lower [LVG] at each time point
  - Over 45-57% LVG reduction in EFZ group AUC
- Pregnancy outcomes:
  - 3/20 pregnancies in EFZ
  - 0 in control
- No controls had LVG <300mcg
- All 3 pregnancies were in LVG 200-300mcg

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

**Summary**

- Reduced efficacy of sub dermal implants in women on EFZ
  - EFZ and subdermal use is increasing exponentially in africa
- Threshold of 150 mcg insufficient in HIV population study group
- Need more data on interactions with other ART



CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

**PROMISE:**  
**Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission**


MG Fowler, M Qin, S Fiscus, JS Currier, P Flynn, J McIntyre, T Chipato, B Makanani, FE Martinson, R Browning, DE Shapiro, and LM Mofenson for The IMPAACT PROMISE 1077BF/1077FF Team

CROI 2015 feedback: www.i-Base.info 36 UK-CAB April 2015



- ### Conclusions
- results support the 2013 WHO recommendations for use of triple maternal ARV regimens in pregnancy to achieve the lowest risk of transmission.
  - triple ARV regimens were associated with higher risk of moderate but not severe adverse maternal and pregnancy outcomes including preterm birth and low birth weight,
  - The difference in risk of early infant deaths in the FTC-TDF triple ARV arm compared to the 3TC-ZDV triple ARV arm was unanticipated and requires further investigation.
- CROI 2015 feedback: www.i-Base.info 39 UK-CAB April 2015


- ### New drugs
- TAF
  - Bevirimat
  - Carbotegravir/rilpivirine (LATTE)
  - DTG week 96 comparison
- CROI 2015 feedback: www.i-Base.info UK-CAB April 2015



### TAF vs. TDF: Baseline Characteristics

	E/C/F/TAF n=866	E/C/F/TDF n=867
Median age, years	33	35
Sex, %		
Female	15	15
Race/ethnicity, %		
Black or African descent	26	25
Hispanic/Latino ethnicity	19	19
Median HIV-1 RNA, log <sub>10</sub> c/mL	4.58	4.58
% with HIV-1 RNA >100,000 c/mL	23	23
Median CD4 count, cells/µL	404	406
% with CD4 count <200	13	14
Median estimated GFR*, mL/min	117	114




\* Cockcroft-Gault  
Wohl D, et al. CROI 2015 feedback: www.i-Base.info. Abstr. 113LB. UK-CAB April 2015



### TAF vs TDF: Adverse Events

	E/C/F/TAF n=866	E/C/F/TDF n=867
<b>% (n) Discontinuations</b>	<b>0.9% (8)</b>	<b>1.5% (13)</b>
<b>AEs in ≥5% of patients, %</b>		
Diarrhea	17	19
Nausea	15	17
Headache	14	13
Upper respiratory tract infection	11	13
Nasopharyngitis	9	9
Fatigue	8	8
Cough	8	7
Vomiting	7	6
Arthralgia	7	5
Back pain	7	7

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015








### BMS-955176: Antiviral Activity and Safety of a Second-Generation HIV-1 Maturation Inhibitor

Carey Hwang<sup>1</sup>, Dirk Schürmann<sup>2</sup>, Christian Sobotha<sup>2</sup>, Heather Sevinsky<sup>1</sup>, Palanikumar Ravindran<sup>1</sup>, Hong Xiao<sup>1</sup>, Neelanjana Ray<sup>1</sup>, Mark Krysta<sup>1</sup>, Ira Dicker<sup>3</sup> and Max Lataillade<sup>3</sup>, for the BMS HIV Development Team

<sup>1</sup> Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA  
<sup>2</sup> Charité Research Organisation GmbH, Charitéplatz 1, 10117 Berlin, Germany  
<sup>3</sup> Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015






### LATTE: Baseline Characteristics

Margolis D, et al. 22nd CROI; Seattle, WA; February 23-26, 2015. Abst. 554LB.

	744 10 mg n=60	744 30 mg n=60	744 60 mg n=61	EFV 600 mg n=62	
<b>Age</b>	Median (y)	32.0	32.5	36.0	32.5
<b>Gender</b>	Male	95%	97%	93%	98%
	White	62%	65%	59%	63%
	African American/African	35%	28%	30%	32%
<b>Ethnicity</b>	Hispanic/Latino	15%	27%	23%	19%
<b>Baseline HIV-1 RNA</b>	Median (log <sub>10</sub> c/mL)	4.281	4.178	4.349	4.343
	>100,000 c/mL	13%	12%	20%	13%
<b>Baseline CD4+</b>	Median (cells/mm <sup>3</sup> )	415.0	404.0	420.0	416.5
	<200 cells/mm <sup>3</sup>	3%	7%	3%	2%
<b>Hepatitis coinfection HCV</b>		0	5 (8%)	4 (7%)	1 (2%)
<b>Investigator-selected dual NRTIs at Day 1</b>	TDF/FTC	37 (62%)	37 (62%)	37 (61%)	38 (61%)
	ABC/3TC	23 (38%)	23 (38%)	24 (39%)	24 (39%)

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015



### LATTE: HIV-1 RNA <50 c/mL

#### Week 96 Treatment Outcomes

Outcome at Week 96	CAB 10 mg	CAB 30 mg	CAB 60 mg	CAB Total	EFV 600 mg
% <50 c/mL at W96 Snapshot (ITT-E)	41/60 (68%)	45/60 (75%)	51/61 (84%)	137/181 (76%)	39/62 (63%)
Protocol-defined Virologic Failure	3 (5%)	2 (3%)	1 (2%)	6 (3%)	6 (10%)
Failure - Adverse Event	1 (2%)	1 (2%)	4 (7%)	6 (3%)	9 (15%)
Failure - HIV-1 RNA ≥50 c/mL	5 (8%)	1 (2%)	2 (3%)	8 (4%)	2 (3%)
Failure - Other* Reasons while ≥50 c/mL	2 (3%)	2 (3%)	1 (2%)	5 (3%)	3 (5%)
Failure - Other* Reasons while <50 c/mL	8 (13%)	9 (15%)	2 (3%)	19 (10%)	3 (5%)
% <50 c/mL at W96 Snapshot (ITT-ME)	41/52 (79%)	45/53 (85%)	51/55 (93%)	137/160 (86%)	39/47 (83%)
Protocol-defined virologic failure	2 (4%)	1 (2%)	0	3 (2%)	2 (4%)
Failure - Adverse Event	1 (2%)	0	1 (2%)	2 (1%)	2 (4%)
Failure - HIV-1 RNA ≥50 c/mL	4 (8%)	1 (2%)	1 (2%)	6 (4%)	2 (4%)
Failure - Other* Reasons while ≥50 c/mL	1 (2%)	1 (2%)	1 (2%)	3 (2%)	0
Failure - Other* Reasons while <50 c/mL	3 (6%)	5 (9%)	1 (2%)	9 (6%)	2 (4%)

Margolis D, et al. 22nd CROI; Seattle, WA; February 23-26, 2015. Abst. 554LB.

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### LATTE: Adverse Events

	CAB 10 mg n=60	CAB 30 mg n=60	CAB 60 mg n=61	EFV 600 mg n=62
Grade 2-4 Drug-related Events (>3% Any Arm)	5 (8%)	8 (13%)	13 (21%)	12 (19%)
Insomnia	1 (2%)	2 (3%)	0	4 (6%)
Depression	0	0	2 (3%)	0
Nausea	0	2 (3%)	3 (5%)	1 (2%)
Fatigue	0	2 (3%)	1 (2%)	1 (2%)
Headache	1 (2%)	1 (2%)	3 (5%)	0
Rash Macular	0	0	0	3 (5%)
% <50 c/mL at W96 Snapshot (ITT-ME)	1 (2%)	2 (3%)	3 (5%)	2 (3%)
Serious AEs	7 (12%)	5 (8%)	7 (11%)	4 (6%)*
Serious AEs (W24+)	5 (8%)	5 (8%)	5 (8%)	2 (3%)
AEs Leading to Withdrawal (>1 Subject)	1 (2%)	2 (3%)	4 (7%)	9 (15%)
Dizziness	0	0	0	2 (4%)
ALT Increased	0	0	2 (3%)**	0

Abstract 554LB, David A Margolis


CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

### LATTE: Adverse Events

	CAB 10 mg n=60	CAB 30 mg n=60	CAB 60 mg n=61	EFV 600 mg n=62
Grade 1-4 ALT Abnormalities	8 (13%)	12 (20%)	17 (28%)	13 (21%)
Select Grade 3-4 Laboratory Abnormalities				
Creatine Phosphokinase (CPK)	7 (12%)	7 (12%)	5 (8%)	9 (15%)
Alanine Aminotransferase (ALT)	0	1 (2%)	2 (3%)**	1 (2%)
Lipase	3 (5%)	2 (3%)	6 (10%)	1 (2%)
Total Bilirubin	0	0	0	0
Total Neutrophils	1 (2%)	1 (2%)	2 (3%)	2 (3%)
Creatinine	0	0	0	0

Margolis D, et al. 22nd CROI; Seattle, WA; February 23-26, 2015. Abst. 554LB.

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015

  
**British HIV Association**  
**BHIVA**

Thanks to researchers for use of slides and BHIVA compilation from 2015 BHIVA "Best of CROI" feedback meetings.

Four talks are web cast at:  
[www.bhiva.org](http://www.bhiva.org)

Original selections led by Julie Fox for prevention studies and Frank Post for ARVs.

CROI 2015 feedback: www.i-Base.info UK-CAB April 2015